Jefferies analyst Eun Yang upgraded CureVac to Buy from Hold with a price target of $21, up from $9, after the company announced preliminary data from its ongoing Phase 1 clinical programs in COVID-19 and seasonal flu. The tested vaccine candidates are being developed in collaboration with GSK.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CVAC: